Moexipril Hydrochloride
FDA-approved product (tablet, oral), marketed as Moexipril Hydrochloride, Univasc.
- Registered studies
- 12
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
- Hypertension
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Ace inhibitors, plain
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae18.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
12registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Moexipril Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Galantamine HydrobromideExisting use: Alzheimer disease, Dementia89.6% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- Chlorhexidine GluconateExisting use: Eye infection, Gingivitis, Infection and 2 more69.3% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives68.0% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- ElvitegravirExisting use: HIV infection, HIV-1 infection, Viral disease60.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more57.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm56.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- CyclosporineExisting use: Conjunctivitis, Corneal disease, Eye disease and 6 more56.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome56.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more54.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia52.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Micafungin SodiumExisting use: Candidiasis52.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- VoclosporinExisting use: Immune system disease, Lupus nephritis52.2% AI-predicted activityagainst K. pneumoniae28 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
NCT07547878 · start 2026-04-30
Registered record
- Registry ID
- NCT07547878
- Conditions
- Chronic Kidney Disease; Type 2 Diabetes
- Interventions
- Finerenone; Semaglutide; Lotensin; Capoten; Enalapril; Monopril; Lisinopril; Univasc; Aceon; Accupril; Altace; Mavik; Edarbi; Atacand; Avapro; Cozaar; Benicar; Micardis; Diovan; Invokana; Farxiga; Jardiance; Ertugliflozin; Brenzavvy; Sotagliflozin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Not yet recruiting
- Start
- 2026-04-30
- Completion
- 2029-03-31
- Enrolment
- 64
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Kidney Disease; Type 2 DiabetesInterventionFinerenone; Semaglutide; Lotensin; Capoten +21 morePhasePhase 4Registry statusNot yet recruitingAssociation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
NCT07262710 · start 2025-12-01
Registered record
- Registry ID
- NCT07262710
- Conditions
- Post-stroke Pneumonia
- Interventions
- angiotensin converting enzyme inhibitors; Calcium Channel Blockers; Angiotensin Receptor Blockers
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Not yet recruiting
- Start
- 2025-12-01
- Completion
- 2026-08-19
- Enrolment
- 13,656
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPost-stroke PneumoniaInterventionangiotensin converting enzyme inhibitors; Calcium Channel Blockers; Angiotensin Receptor BlockersPhaseNot recordedRegistry statusNot yet recruitingEffect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
NCT05498675 · start 2021-09-01
Registered record
- Registry ID
- NCT05498675
- Conditions
- Sacubitril/Valsartan; Hypertension; Obesity
- Interventions
- Sacubitril / Valsartan Oral Tablet [Entresto]; ACEI/ARB
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Recruiting
- Start
- 2021-09-01
- Completion
- 2027-06-30
- Enrolment
- 180
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSacubitril/Valsartan; Hypertension; ObesityInterventionSacubitril / Valsartan Oral Tablet [Entresto]; ACEI/ARBPhaseNot recordedRegistry statusRecruitingACEI or ARB and COVID-19 Severity and Mortality in US Veterans
NCT04467931 · start 2020-01-19
Registered record
- Registry ID
- NCT04467931
- Conditions
- Hypertension; COVID
- Interventions
- ACEI/ARB; Non-ACEI/ARB; ACEI; ARB
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2020-01-19
- Completion
- 2020-12-31
- Enrolment
- 22,213
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertension; COVIDInterventionACEI/ARB; Non-ACEI/ARB; ACEI; ARBPhaseNot recordedRegistry statusCompletedChronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery
NCT01669434 · start 2015-06-01
Registered record
- Registry ID
- NCT01669434
- Conditions
- Hypotension on Induction
- Interventions
- ACEI continuation; ACEI omission
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2015-06-01
- Completion
- 2016-12-01
- Enrolment
- 291
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypotension on InductionInterventionACEI continuation; ACEI omissionPhasePhase 4Registry statusCompletedACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients
NCT01867047 · start 2013-06
Registered record
- Registry ID
- NCT01867047
- Conditions
- Adverse Effects of Angiotensin-converting-enzyme Inhibitors; Hypotension
- Interventions
- ACE-I Cessation group; ACE-I Continuation group
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Terminated
- Start
- 2013-06
- Completion
- 2016-06-24
- Enrolment
- 59
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdverse Effects of Angiotensin-converting-enzyme Inhibitors; HypotensionInterventionACE-I Cessation group; ACE-I Continuation groupPhaseNot applicableRegistry statusTerminatedMoexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions
NCT00834067 · start 2003-10
Registered record
- Registry ID
- NCT00834067
- Conditions
- Healthy
- Interventions
- Moexipril HCl/hydrochlorothiazide 15/25 mg tablets; UNIRETIC® 15/25 mg tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2003-10
- Completion
- 2003-11
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionMoexipril HCl/hydrochlorothiazide 15/25 mg tablets; UNIRETIC® 15/25 mg tabletsPhasePhase 1Registry statusCompletedMoexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions
NCT00835042 · start 2003-10
Registered record
- Registry ID
- NCT00835042
- Conditions
- Healthy
- Interventions
- Moexipril HCl/hydrochlorothiazide 15/25 mg tablets; UNIRETIC® 15/25 mg tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2003-10
- Completion
- 2003-11
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionMoexipril HCl/hydrochlorothiazide 15/25 mg tablets; UNIRETIC® 15/25 mg tabletsPhasePhase 1Registry statusCompletedRenin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension
NCT00684489 · start 2003-09
Registered record
- Registry ID
- NCT00684489
- Conditions
- Hypertension
- Interventions
- clinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2003-09
- Completion
- 2005-09
- Enrolment
- 52
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionclinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.PhaseNot applicableRegistry statusCompletedMoexipril for Primary Biliary Cirrhosis
NCT00588302 · start 2003-06
Registered record
- Registry ID
- NCT00588302
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Moexipril
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-06
- Completion
- 2007-06
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPrimary Biliary CirrhosisInterventionMoexiprilPhasePhase 2Registry statusCompletedA Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions
NCT00990301
Registered record
- Registry ID
- NCT00990301
- Conditions
- Healthy
- Interventions
- Moexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc.; Uniretic® 15mg/25mg Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionMoexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc.; Uniretic® 15mg/25mg TabletsPhasePhase 1Registry statusCompletedA Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions
NCT00992862
Registered record
- Registry ID
- NCT00992862
- Conditions
- Healthy
- Interventions
- Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.; Univasc® 15mg Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionMoexipril HCl 15mg Tablets, Paddock Laboratories, Inc.; Univasc® 15mg TabletsPhasePhase 1Registry statusCompleted